Lonza Potelligent CHOK1SV host cell line

Friday, 20 November, 2009 | Supplied by: Capsugel Australia Pty Ltd


Potelligent CHOK1SV, a host cell line for manufacturing recombinant antibodies, combines BioWa’s glycosylation Potelligent technology with Lonza’s GS Gene Expression System and CHOK1SV.

The cell line retains the features of a high-productivity cell line (robust, high-yielding, scalable) and the bioprocess platform for CHOK1SV is repeatable in the new cell line.

Antibodies produced by the new cell line: exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) even with the low-ADCC allotype of CD16, overcoming CD16 polymorphism; can exert potent cytotoxic effects when their target antigen is low; work in whole blood; and retain required features of antibodies, such as Protein A binding.

Online: lonzabioscience.com.au
Phone: 1300 657508
Related Products

Bioss In Vivo Biosimilar Antibodies

Bioss In Vivo Biosimilar Antibodies are research-grade copies of therapeutic antibodies that are...

LSBio virology research products

LSBio offers antibodies, proteins, ELISA kits, assay kits and chemical compounds used by...

Beckman Coulter Life Sciences IR820 and IR870 infrared dye antibody conjugates

The products provide research flow cytometry labs with a low-noise solution, including single...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd